Skip to main content
SpringerLink
Log in

Pegylated-Liposomal Doxorubicin (Doxil®) in the Treatment of AIDS-Related Kaposi’s Sarcoma

  • Chapter
Long Circulating Liposomes: Old Drugs, New Therapeutics

Part of the book series: Biotechnology Intelligence Unit ((BIOIU))

Abstract

In 1981 reports of the development of Kaposi’s sarcoma in previously healthy young homosexual men heralded the onset of the epidemic of acquired immunodeficiency syndrome (AIDS). 1–3 Kaposi’s sarcoma is the most common neoplasm in persons infected with the human immunodeficiency virus (HIV), having been the initial (“AIDS-defining”) diagnosis in 15% of the patients with AIDS in the United States.4 It has been estimated that AIDS-related Kaposi’s sarcoma (AIDS-KS) has a prevalence of about 20,000 cases in this country.5 While the overall incidence seems to be declining, the actual morbidity and mortality ascribed to AIDS-KS has increased, probably as a result of improved therapy of opportunistic infections without concurrent improvements in the treatment of AIDS-KS.6,7 Several modalities have been employed successfully to treat AIDS-KS, but their toxicities, as well as the patients’ underlying immunodeficiency, have limited their usefulness. Also, AIDS-KS produces visceral involvement, especially in the lungs, for which current treatments are less effective than for cutaneous disease. 8,9

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Friedman-Kein A, Laubenstein L, Marmor M et al. Kaposi’s sarcom and pneumocystic pneumonia among homosexual men-New York City and California. MMWR 1981; 30: 305–308.

    Google Scholar 

  2. Hymes KB, Cheung TL, Green JB et al. Kaposi’s sarcoma in homosexual men: a report of 8 cases. Lancet 1981; 2: 598–600.

    Article  PubMed  CAS  Google Scholar 

  3. Masur H, Michilis MA, Green JB et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestations of cellular immune dysfunction. N Engl J Med 1981; 30: 51431–1438.

    Google Scholar 

  4. Beral V, Peterman TA, Berkelman RL et al. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 1: 123–128.

    Article  Google Scholar 

  5. Northfelt DW. AIDS-related Kaposi’s sarcoma: still a problem, still an opportunity. J Clin Oncol 1994; 12: 1109–1110.

    PubMed  CAS  Google Scholar 

  6. Peters BS, Beck EJ, Coleman DG et al. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. Br J Med 1991; 302: 203–207.

    Article  CAS  Google Scholar 

  7. Selik RM, Chu SY, Ward JW. Trends in infectious disease and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995; 123:933–936.

    Google Scholar 

  8. Gill PS, Akil B, Colletti P et al. Pulmonary Kaposi’s sarcoma: clinical findings and results of therapy. Am J Med 1989; 87: 57–61.

    Article  PubMed  CAS  Google Scholar 

  9. Kaplan LD, Hopewell PC, Jaffe H et al. Kaposi’s sarcoma involving the lung in patients with acquired immunodeficiency syndrome. J Acquir Immune Defic Synd 1988; 1: 23–30.

    CAS  Google Scholar 

  10. Centers for Disease Control. Epidemiologic aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infections. N Engl J Med1982: 306: 248–252.

    Google Scholar 

  11. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph 1872; 4: 265–273.

    Google Scholar 

  12. Taylor JF, Templeton AC, Vogel CL et al. Kaposi’s sarcoma in Uganda: a clinicopathological study. Int J Cancer 1971; 3: 122–135.

    Article  Google Scholar 

  13. Harwood AR, Osoba D, Hofstader SL et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med 1979; 67: 759–765.

    Article  PubMed  CAS  Google Scholar 

  14. Penn I. Tumors of the immunocompromised patient. Ann Rev Med 1988; 39: 63–73.

    Article  PubMed  CAS  Google Scholar 

  15. Lemp GF, Payne SF, Neal D et al. Survival trends for patients with AIDS. JAMA 1990; 263: 402–406.

    Article  PubMed  CAS  Google Scholar 

  16. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and those without HIV infection. N Engl J Med 1995; 332; 1181–1185.

    Article  PubMed  CAS  Google Scholar 

  17. Northfelt DW. Treatment of Kaposi’s sarcoma: current guidelines and future perspectives. Drugs 1994; 48: 569–582.

    Article  PubMed  CAS  Google Scholar 

  18. Gill PS, Rarick M, McCutchan JA et al. Systemic treatment of AIDS-related Kaposi’s sarcoma: results of a randomized trial. Am J Med 1991; 90: 427–433.

    PubMed  CAS  Google Scholar 

  19. Gabizon A, Chisin R, Amselem S et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated Adriamycin. Br J Cancer 1991; 64: 1125–1132.

    Article  PubMed  CAS  Google Scholar 

  20. Gabizon AA, Barenholz Y, Bialer M. Prolongation of circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharmaceut Res 1993; 10:703–708.

    Google Scholar 

  21. Huang SK, Mahew E, Gilani S. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774–6781.

    PubMed  CAS  Google Scholar 

  22. Huang SK, Martin FJ, Jay G et al. Extravasation and transcytosis of liposomes in Kaposi’s sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993; 143: 10–14.

    PubMed  CAS  Google Scholar 

  23. Vaage J, Barbera-Guillem E, Abra R et al. Tissue distributions and therapeutic effects of intravenous free and liposomal doxorubicin against human prostatic carcinoma xenografts. Cancer 1994; 73: 147H - 1484.

    Google Scholar 

  24. Northfelt DW, Martin FJ, Working P et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996; 36: 55–63.

    Article  PubMed  CAS  Google Scholar 

  25. Northfelt DW. Stealth® liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi’s sarcoma (AIDS-KS) lesions than to normal skin. Proc ASCO 1994; abstract 5.

    Google Scholar 

  26. Hengge UR, Brockmeyer NH, Baumann M et al. Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma. Lancet 1993; 342: 497.

    Article  PubMed  CAS  Google Scholar 

  27. Simpson JK, Miller RF, Spittle MF. Liposomal doxorubicin for treatment of AIDS-related Kaposi’s sarcoma. Clin Oncol 1993; 5: 372–374.

    Article  CAS  Google Scholar 

  28. Bogner JR, Kronawitter U, Rolinski B et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Synd 1994; 7: 463–468.

    CAS  Google Scholar 

  29. James ND, Coker RJ, Tomlinson D et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi’s sarcoma in AIDS. Clin Oncol 1994; 6: 294–296.

    Article  CAS  Google Scholar 

  30. Sturzl M, Zeitz C, Eisenburg B et al. Liposomal doxorubicin in the treatment of AIDS-associated Kaposi’s sarcoma: clinical, histological and cell biological evaluation. Res Virol 1994; 145: 261–269.

    Article  PubMed  CAS  Google Scholar 

  31. Wagner D, Kern WV, Kern P. Liposomal doxorubicin in AIDS-related Kaposi’s sarcoma: long-term experiences. Clin Investig 1994; 72: 417–423.

    PubMed  CAS  Google Scholar 

  32. Harrison M, Tomlinson D, Stewart S. Liposome-entrapped doxorubicin: an active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1995; 13: 914–920.

    PubMed  CAS  Google Scholar 

  33. Northfelt DW, Dezube BJ, Thommes JA et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653–659.

    PubMed  CAS  Google Scholar 

  34. Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immunodeficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989; 7: 201–1207.

    Google Scholar 

  35. Fischl MA, Krown SE, O’Boyle KP et al. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi’s sarcoma. J Acquir Immun Defic Synd 1993; 6: 259–264.

    CAS  Google Scholar 

  36. Gill P, Rarick M, Bernstein-Singer M et al. Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990; 13: 315–319.

    Article  PubMed  CAS  Google Scholar 

  37. Rarick MU, Gill PS, Montgomery T et al. Treatment of epidemic Kaposi’s sarcoma with combination chemotherapy (vincristine and bleomycin) and zidovudine. Ann Oncol 1990; 1: 147–149.

    PubMed  CAS  Google Scholar 

  38. Northfelt DW, Dezube BJ, Thommes JA et al. Randomized comparative trial of Doxil* vs. Adriamycin, bleomycin, and vincristine (ABV) in the treatment of severe AIDS-related Kaposi’s sarcoma (AIDS-KS). 3rd Conference on Retroviruses and Opportunistic Infections 1996; abstract 379.

    Google Scholar 

  39. Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of Doxil° vs. bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. XI International Conference on AIDS 1996; abstract LB.B.6026.

    Google Scholar 

  40. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. JNCI 1995; 87: 1556–1557.

    Article  PubMed  CAS  Google Scholar 

  41. Berry G, Billingham M, Alderman E et al. Reduced cardiotoxicity of Doxil (pegylated liposomal doxorubicin) in AIDS Kaposi’s sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc ASCO 1996; abstract 843.

    Google Scholar 

Download references

Authors
  1. Donald W. Northfelt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Genetic Therapy, Inc., Gaithersburg, Maryland, USA

    Martin C. Woodle Ph.D.

  2. Department of Pharmaceutics, University of Utrecht, Utrecht, The Netherlands

    Gerrit Storm Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Northfelt, D.W. (1998). Pegylated-Liposomal Doxorubicin (Doxil®) in the Treatment of AIDS-Related Kaposi’s Sarcoma. In: Woodle, M.C., Storm, G. (eds) Long Circulating Liposomes: Old Drugs, New Therapeutics. Biotechnology Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22115-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-22115-0_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-22117-4

  • Online ISBN: 978-3-662-22115-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation